MARC details
| 000 -LEADER |
|---|
| fixed length control field |
01813nam a2200229Ia 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
MX-MdCICY |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20250625162412.0 |
| 040 ## - CATALOGING SOURCE |
|---|
| Transcribing agency |
CICY |
| 090 ## - LOCALLY ASSIGNED LC-TYPE CALL NUMBER (OCLC); LOCAL CALL NUMBER (RLIN) |
|---|
| Classification number (OCLC) (R) ; Classification number, CALL (RLIN) (NR) |
B-18406 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
250602s9999 xx |||||s2 |||| ||und|d |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer. |
| 490 0# - SERIES STATEMENT |
|---|
| Volume/sequential designation |
In Seminars in Cancer Biology. Academic Press, 59, p.3-22, 2019 |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc. |
The phosphoinositide 3-kinase (PI3K)pathway, one of the most commonly activated signaling pathways in human cancers, plays a crucial role in the regulation of cell proliferation, differentiation, and survival. This pathway is usually activated by receptor tyrosine kinases (RTKs), whose constitutive and aberrant activation is via gain-of-function mutations, chromosomal rearrangement, gene amplification and autocrine. Blockage of PI3K pathway by targeted therapy on RTKs with tyrosine kinases inhibitors (TKIs)and monoclonal antibodies (mAbs)has achieved great progress in past decades; however, there still remain big challenges during their clinical application. In this review, we provide an overview about the most frequently encountered alterations in RTKs and focus on current therapeutic agents developed to counteract their aberrant functions, accompanied with discussions of two major challenges to the RTKs-targeted therapy in cancer - resistance and toxicity. |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
PHOSPHOINOSITIDE 3-KINASE (PI3K)PATHWAY |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
RECEPTOR TYROSINE KINASES (RTKS) |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
TYROSINE KINASES INHIBITORS (TKIS) |
| 650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
MONOCLONAL ANTIBODIES (MABS) |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Jiang, W. |
| 700 12 - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Ji, M. |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
<a href="https://drive.google.com/file/d/1Ld3WSpchtI-MOa4Z6byKzK1uXnLSXuuK/view?usp=drivesdk">https://drive.google.com/file/d/1Ld3WSpchtI-MOa4Z6byKzK1uXnLSXuuK/view?usp=drivesdk</a> |
| Public note |
Para ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Clasificación local |
| Koha item type |
Documentos solicitados |
